IFP Advisors’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$94K Buy
9,470
+1,607
+20% +$14.1K ﹤0.01% 2011
2026
Q2
$63.8K Buy
7,863
+955
+14% +$6.99K ﹤0.01% 2250
2026
Q1
$44.1K Buy
6,908
+6,704
+3,286% +$43.2K ﹤0.01% 2322
2025
Q4
$1.21K Buy
204
+155
+316% +$823 ﹤0.01% 4009
2025
Q3
$260 Buy
49
+9
+23% +$38 ﹤0.01% 4343
2025
Q2
$199 Buy
40
+26
+186% +$83 ﹤0.01% 4630
2025
Q1
$41 Hold
14
– – ﹤0.01% 4057
2024
Q4
$43 Buy
+14
New +$41 ﹤0.01% 4301
2021
Q3
– Sell
-1,463
Closed -$12K – 3434
2021
Q2
$12K Buy
1,463
+540
+59% +$5.47K ﹤0.01% 2147
2021
Q1
$8K Buy
923
+128
+16% +$1.43K ﹤0.01% 2235
2020
Q4
$7K Sell
795
-525
-40% -$5.32K ﹤0.01% 2203
2020
Q3
$12K Buy
+1,320
New +$13.4K ﹤0.01% 1844
2018
Q3
– Sell
-2
Closed – – 3965
2018
Q2
$0 Hold
2
– – ﹤0.01% 4009
2018
Q1
$0 Hold
2
– – ﹤0.01% 3808
2017
Q4
$0 Buy
+2
New +$224 ﹤0.01% 4027

Other funds holding PBYI

IFP Advisors's PBYI Position: Q3 2026 in Review

IFP Advisors increased its Puma Biotechnology (PBYI) stake by 20% in Q3 2026, buying an estimated $14.1K and bringing the position to 9,470 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #2011.

IFP Advisors first reported a position in PBYI in Q4 2017 and has held it in 15 quarters since. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.

  • IFP Advisors held 9,470 shares of Puma Biotechnology worth $94K as of Q3 2026.
  • IFP Advisors bought 1,607 Puma Biotechnology shares in Q3 2026, an estimated $14.1K.
  • Puma Biotechnology made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #2011 holding.
  • IFP Advisors first reported a position in Puma Biotechnology in Q4 2017 and has held it in 15 quarters since.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.